Unsedated peroral wireless pH capsule placement vs. standard pH testing: a randomized study and cost analysis

Christopher N Andrews, Daniel C Sadowski, Adriana Lazarescu, Chad Williams, Emil Neshev, Martin Storr, Flora Au, Steven J Heitman, Christopher N Andrews, Daniel C Sadowski, Adriana Lazarescu, Chad Williams, Emil Neshev, Martin Storr, Flora Au, Steven J Heitman

Abstract

Background: Wireless capsule pH-metry (WC) is better tolerated than standard nasal pH catheter (SC), but endoscopic placement is expensive.

Aims: to confirm that non-endoscopic peroral manometric placement of WC is as effective and better tolerated than SC and to perform a cost analysis of the available esophageal pH-metry methods.

Methods: Randomized trial at 2 centers. Patients referred for esophageal pH testing were randomly assigned to WC with unsedated peroral placement or SC after esophageal manometry (ESM). Primary outcome was overall discomfort with pH-metry. Costs of 3 different pH-metry strategies were analyzed: 1) ESM + SC, 2) ESM + WC and 3) endoscopically placed WC (EGD + WC) using publicly funded health care system perspective.

Results: 86 patients (mean age 51 ± 2 years, 71% female) were enrolled. Overall discomfort score was less in WC than in SC patients (26 ± 4 mm vs 39 ± 4 mm VAS, respectively, p = 0.012) but there were no significant group differences in throat, chest, or overall discomfort during placement. Overall failure rate was 7% in the SC group vs 12% in the WC group (p = 0.71). Per patient costs ($Canadian) were $1475 for EGD + WC, $1014 for ESM + WC, and $906 for ESM + SC. Decreasing the failure rate of ESM + WC from 12% to 5% decreased the cost of ESM + WC to $991. The ESM + SC and ESM + WC strategies became equivalent when the cost of the WC device was dropped from $292 to $193.

Conclusions: Unsedated peroral WC insertion is better tolerated than SC pH-metry both overall and during placement. Although WC is more costly, the extra expense is partially offset when the higher patient and caregiver time costs of SC are considered.

Trial registration: Clinicaltrials.gov Identifier NCT01364610.

References

    1. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol. 2007;102:668–685. doi: 10.1111/j.1572-0241.2006.00936.x.
    1. Fass R, Hell R, Sampliner RE, Pulliam G, Graver E, Hartz V, Johnson C, Jaffe P. Effect of ambulatory 24-hour esophageal pH monitoring on reflux-provoking activities. Dig Dis Sci. 1999;44:2263–2269. doi: 10.1023/A:1026608804938.
    1. Wong WM, Bautista J, Dekel R, Malagon IB, Tuchinsky I, Green C, Dickman R, Esquivel R, Fass R. Feasibility and tolerability of transnasal/per-oral placement of the wireless pH capsule vs. traditional 24-h oesophageal pH monitoring--a randomized trial. Aliment Pharmacol Ther. 2005;21:155–163. doi: 10.1111/j.1365-2036.2005.02313.x.
    1. About the Bravo pH monitoring system. .
    1. des Varannes SB, Mion F, Ducrotte P, Zerbib F, Denis P, Ponchon T, Thibault R, Galmiche JP. Simultaneous recordings of oesophageal acid exposure with conventional pH monitoring and a wireless system (Bravo) Gut. 2005;54:1682–1686. doi: 10.1136/gut.2005.066274.
    1. Pandolfino JE, Schreiner MA, Lee TJ, Zhang Q, Boniquit C, Kahrilas PJ. Comparison of the Bravo wireless and Digitrapper catheter-based pH monitoring systems for measuring esophageal acid exposure. Am J Gastroenterol. 2005;100:1466–1476. doi: 10.1111/j.1572-0241.2005.41719.x.
    1. Pandolfino JE, Zhang Q, Schreiner MA, Ghosh S, Roth MP, Kahrilas PJ. Acid reflux event detection using the Bravo wireless versus the Slimline catheter pH systems: why are the numbers so different? Gut. 2005;54:1687–1692. doi: 10.1136/gut.2005.064691.
    1. Bechtold ML, Holly JS, Thaler K, Marshall JB. Bravo (wireless) ambulatory esophageal pH monitoring: how do day 1 and day 2 results compare? World J Gastroenterol. 2007;13:4091–4095.
    1. Bhat YM, McGrath KM, Bielefeldt K. Wireless esophageal pH monitoring: new technique means new questions. J Clin Gastroenterol. 2006;40:116–121. doi: 10.1097/01.mcg.0000196188.57543.75.
    1. Lacy BE, O'Shana T, Hynes M, Kelley ML, Weiss JE, Paquette L, Rothstein RI. Safety and tolerability of transoral Bravo capsule placement after transnasal manometry using a validated conversion factor. Am J Gastroenterol. 2007;102:24–32. doi: 10.1111/j.1572-0241.2006.00889.x.
    1. Lee WC, Yeh YC, Lacy BE, Pandolfino JE, Brill JV, Weinstein ML, Carlson AM, Williams MJ, Wittek MR, Pashos CL. Timely confirmation of gastro-esophageal reflux disease via pH monitoring: estimating budget impact on managed care organizations. Curr Med Res Opin. 2008;24:1317–1327. doi: 10.1185/030079908X280680.
    1. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada (3rd Edition). Ottawa. 2006.
    1. Pandolfino JE, Fox MR, Bredenoord AJ, Kahrilas PJ. High-resolution manometry in clinical practice: utilizing pressure topography to classify oesophageal motility abnormalities. Neurogastroenterol Motil. 2009;21:796–806. doi: 10.1111/j.1365-2982.2009.01311.x.
    1. Pandolfino JE, Kahrilas PJ. AGA technical review on the clinical use of esophageal manometry. Gastroenterology. 2005;128:209–224. doi: 10.1053/j.gastro.2004.11.008.
    1. Huskisson EC. Measurement of pain. J Rheumatol. 1982;9:768–769.
    1. Wenner J, Johnsson F, Johansson J, Oberg S. Wireless esophageal pH monitoring is better tolerated than the catheter-based technique: results from a randomized cross-over trial. Am J Gastroenterol. 2007;102:239–245. doi: 10.1111/j.1572-0241.2006.00939.x.
    1. Kelly AM. Does the clinically significant difference in visual analog scale pain scores vary with gender, age, or cause of pain? Acad Emerg Med. 1998;5:1086–1090. doi: 10.1111/j.1553-2712.1998.tb02667.x.
    1. Kelly AM. The minimum clinically significant difference in visual analogue scale pain score does not differ with severity of pain. Emerg Med J. 2001;18:205–207. doi: 10.1136/emj.18.3.205.
    1. Todd KH, Funk KG, Funk JP, Bonacci R. Clinical significance of reported changes in pain severity. Ann Emerg Med. 1996;27:485–489. doi: 10.1016/S0196-0644(96)70238-X.
    1. Bradley AG, Crowell MD, DiBaise JK, Kim HJ, Burdick GE, Fleischer DE, Sharma VK. Comparison of the impact of wireless versus catheter-based pH-metry on daily activities and study-related symptoms. J Clin Gastroenterol. 2011;45:100–106. doi: 10.1097/MCG.0b013e3181e5d32a.
    1. Lacy BE, Chehade R, Crowell MD. A prospective study to compare a symptom-based reflux disease questionnaire to 48-h wireless pH monitoring for the identification of gastroesophageal reflux (revised 2-26-11) Am J Gastroenterol. 2011;106:1604–1611. doi: 10.1038/ajg.2011.180.
    1. Heitman SJ, Au F, Manns BJ, McGregor SE, Hilsden RJ. Nonmedical costs of colorectal cancer screening with the fecal occult blood test and colonoscopy. Clin Gastroenterol Hepatol. 2008;6:912–917. doi: 10.1016/j.cgh.2008.03.006. e911.
    1. Lee H, Manns B, Taub K, Ghali WA, Dean S, Johnson D, Donaldson C. Cost analysis of ongoing care of patients with end-stage renal disease: the impact of dialysis modality and dialysis access. Am J Kidney Dis. 2002;40:611–622. doi: 10.1053/ajkd.2002.34924.
    1. Ward EM, Devault KR, Bouras EP, Stark ME, Wolfsen HC, Davis DM, Nedrow SI, Achem SR. Successful oesophageal pH monitoring with a catheter-free system. Aliment Pharmacol Ther. 2004;19:449–454. doi: 10.1111/j.1365-2036.2004.01868.x.
    1. Chander B, Hanley-Williams N, Deng Y, Sheth A. 24 Versus 48-hour Bravo pH Monitoring. J Clin Gastroenterol. 2012;46:197–200. doi: 10.1097/MCG.0b013e31822f3c4f.

Source: PubMed

3
Prenumerera